premeeting intelligence for:

Albert Bourla

,

Chairman and Chief Executive Officer at Pfizer

Albert Bourla

Chairman and Chief Executive Officer at Pfizer
Decisive
Assertive
Fast-Paced
Determined
Persuasive
Ambitious
Dynamic
Visionary
Spontaneous
Pioneering
Adventurous
Casual
Enthusiastic
Personable
Adaptable
Optimistic
Inventive
Approachable
Warm
Hospitable
Intuitive
Friendly
Accommodating
Diplomatic
Composed
Thoughtful
Agreeable
Careful
Modest
Consistent
Conscientious
Perceptive
Calm
Diligent
Meticulous
Collected
Accurate
Rational
Reserved
Strong-willed
Skeptical
Straightforward
Efficient
Candid
Steadfast
Focused
Vigorous
Persistent
Location:
New York, New York, United States
Education:
Aristotle University of Thessaloniki - Doctor of Philosophy (Ph.D.)
Overview:
  • CEO of Pfizer since Jan 2019, overseeing strategic operations.
  • Led Pfizer Innovative Health as Group President (Feb 2016-Dec 2017), directing 6 business groups in oncology, vaccines, and rare diseases.
  • Managed Pfizer's Established Products Business Unit (2010-Dec 2013), handling off-patent portfolio, contributing to business success.
Quotes

ON CONFIDENT COMMITMENT...

"First of all, it is a signal that I have high confidence and I put my money where my mouth is. So I'm all in." source

ON REGULATORY INVESTMENT...

"How is it possible to have a law to tell someone not to invest in small molecules, only invest in large molecules?" source

ON MANAGMENT PERSPECTIVE...

"I think we could have managed it differently, but eventually we are in the right place as to what the situation is." source

DISC Type:
Captain (D)
DISC Type:
Driver (Di)
DISC Type:
Initiator (DI)
DISC Type:
Influencer (Id)
DISC Type:
Motivator (I)
DISC Type:
Encourager (Is)
DISC Type:
Harmonizer (IS)
DISC Type:
Counselor (Si)
DISC Type:
Supporter (S)
DISC Type:
Planner (Sc)
DISC Type:
Stabilizer (SC)
DISC Type:
Editor (Cs)
DISC Type:
Analyst (C)
DISC Type:
Skeptic (Cd)
DISC Type:
Questioner
DISC Type:
Architect (Dc)
How to communicate
Focus on their need for control and results, be direct and to the point.
Do
Provide specific details about the product's features and benefits
Highlight how the product will solve their problems and make their life easier
Don't
Beat around the bush or offer vague information
Be too pushy or salesy
When communicating with them, focus on being direct, confident, and results-oriented.
Do
Speak in a fast-paced, confident tone
Focus on the bottom line and how your product can help them achieve their goals
Don't
Use too much jargon or technical language
Waste time on small talk or irrelevant details
Focus on big ideas, big concepts, and fast action over analysis.
Do
Use a direct and assertive tone
Emphasize results and benefits over features
Don't
Use overly flowery language or too many details
Be pushy or aggressive
Communicate with energy and a lively approach. Engage them by communicating clearly and vividly.
Do
Use inspiring language and be enthusiastic
Show them how the product can enhance their social status or reputation
Don't
Be too technical or confusing
Focus solely on features without considering how it can improve their life
Communicate in a friendly, casual manner and highlight the benefits of the product. Avoid criticism or confrontation.
Do
Use a light-hearted approach to build rapport
Highlight how the product can benefit their life or work
Don't
Be overly critical or confrontational
Use overly technical or confusing language
Interact with them in a friendly, agreeable manner with a light-hearted approach. Avoid criticism and confrontation.
Do
Wrap your pitch with positivity and emotional language
Include personalized, warm greetings and sincere sign off
Don't
Use forceful or high-pressure language
Talk too much about past experience without explaining the important insights
Focus on building a personal relationship and finding common ground. Speak positively and offer reassurance about the product.
Do
Engage them in conversation and find out their interests and concerns
Offer personalized recommendations and highlight how the product can meet their needs
Don't
Push too hard or use aggressive sales tactics
Dismiss or minimize their concerns or objections
Provide detailed information and use a friendly, personal tone
Do
Explain how your product can meet their specific needs
Use stories or examples that they can relate to
Don't
Use technical language or jargon
Push for a quick decision without building rapport first
Provide a warm, friendly greeting and use positive, upbeat language. Focus on building a relationship and show acceptance for who they are.
Do
Use friendly, expressive language
Refer to common interests and associations
Don't
Use a serious, businesslike tone
Bring up your flaws before they do
Focus on building a relationship and connecting with them on a personal level.
Do
Use a warm, friendly tone
Ask about their interests and hobbies
Don't
Use overly technical language
Pressure them into making a decision
Be friendly and focus on building a relationship with them. Use a light-hearted approach and avoid criticism or confrontation.
Do
Focus on building a friendly relationship
Validate their opinions and approach with positive language
Don't
Use forceful or high-pressure language
Force an aggressive sales pitch
Use a straightforward and logical approach when communicating with them
Do
Provide data and logical reasoning to support your claims
Use clear and concise language
Don't
Use overly expressive or emotional language
Use lots of anecdotes or storytelling
Use a serious, businesslike tone and focus on details, data, and results.
Do
Focus on their toughest problems.
Send additional data to support your pitch
Don't
Bring up your flaws before they do
Be unrealistically optimistic
Focus on providing logical reasoning and factual information. Be patient and answer their questions with clear and concise responses.
Do
Provide data-driven reasons for your product
Answer their questions with a well-thought-out response
Don't
Use overly expressive language
Speak in an overly casual manner
Focus on concrete data, specifics, and logistics. Avoid fluffy language and hype.
Do
Provide clear data and statistics to support the product
Present a clear, logical argument for why the product is worth investing in
Don't
Spend too much time on abstract concepts or big ideas
Get sidetracked with small details or anecdotes
When communicating with them, focus on being clear, concise, and results-oriented.
Do
Provide clear and concise information about the product and its benefits
Focus on results and practical details
Don't
Use overly descriptive or flowery language
Waste time on social chatter or small talk
Executive priorities
  • Advance Pfizer's innovative research pipeline, focusing on breakthrough therapies.
  • Strengthen global market presence through strategic partnerships and acquisitions.
  • Enhance operational efficiency to streamline production and supply chain.
  • Foster a culture of diversity and inclusion to drive innovation and employee engagement.
Media
Fierce Pharma

With Pfizer struggling in 2023, CEO Albert Bourla hit with 35% pay cut to $21.6M

With Pfizer’s share price falling by 44% and revenues tumbling by 41%, CEO Albert Bourla also took a significant cut in his pay receiving $21.6 million one year after he made $33 million.

CNBC

Pfizer beats earnings estimates, raises outlook on cost cuts and smaller-than-feared drop in Covid drug sales

Pfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook.

Barron's

Pfizer’s Bourla Bets His Pension on Company Stock as CEO Defends Drug Firm

Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the biopharma CEO wants investors to believe.

Personality traits
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Build rapport
  • Be concise and to the point
  • Ask what he wants from the call
  • Speak with confident language
Gather information
  • Get through the most important questions up front
  • Learn what his competition is doing
  • Learn about his team's current efficiency
Discuss budget
  • Allow some room for him to negotiate
  • Explain how he can save more money in the future
  • Compare your pricing with competitors
Drive action
  • Focus on the advantages he will gain
  • Point out the challenges he will face
  • Explain how taking action will help him make progress
Negotiate
  • End the discussion and revisit it later if he is being too firm
  • Articulate your personal and mutual goals clearly
  • Challenge both parties to come up with a better solution
Work together
  • Give him a deadline for answering
  • Ask him outright
  • Resist the temptation to apologize

Pfizer

For 175 years, Pfizer drives daring scientific innovation, delivering transformative therapies shaping healthcare's future.
Industry:
Pharmaceuticals
Headquarters:
New York, New York, United States
Revenue:
$58.50B
Employees:
83,000

How to negotiate

Keep the discussion casual, but be prepared for candid pushback, at times.
Keep your demo concise and to the point
Keep your demo concise and to the point
Keep your demo concise and to the point
Company Milestones
  • 1886: Pfizer founded, pioneering pharmaceutical breakthroughs.
  • 1955: Polio vaccine development.
  • 1996: Viagra revolutionizes ED treatment.
  • 2009: Wyeth acquisition expands portfolio.
  • 2024: Pfizer marks 175 years of advancing global health.

Demo your product

Notice how he uses your product and let him have fun trial-and-erroring on his own.
Keep your demo concise and to the point
Keep your demo concise and to the point
Top Products
  • Viagra: Leading ED treatment.
  • Prevnar 13: Advanced pneumonia vaccine.
  • Xeljanz: Innovative treatment for arthritis.
  • Ibrance: Breakthrough therapy for breast cancer.
  • Eliquis: Anticoagulant reducing stroke risk.
  • BNT162b2 (Comirnaty): Pfizer's COVID-19 vaccine.
Key Executives
  • Dr. Albert Bourla - Chairman and Chief Executive Officer
  • Sally Susman - Chief Corporate Affairs Officer, Executive Vice President
  • Payal Sahni Becher - Chief People Experience Officer, Executive Vice President
  • Mike McDermott - Chief Global Supply Officer, Executive Vice President
  • Aamir Malik - Chief U.S. Commercial Officer, Executive Vice President
  • Doug Lankler - General Counsel, Executive Vice President
  • Rady Johnson - Chief Compliance, Quality and Risk Officer, Executive Vice President
  • Lidia Fonseca - Chief Digital and Technology Officer, Executive Vice President
Company Stock Performance
Key News
Reuters

Pfizer to outsource some drug production, focus on coronavirus vaccine

Pfizer did not specify which companies within its network it is in active discussions with about shifting production.

May, 2020

CNBC

Pfizer-BioNTech says Covid vaccine is 100% effective in kids ages 12 to 15

Pfizer said its coronavirus vaccine was 100% effective in preventing Covid-19 in children ages 12 to 15.

March, 2021

BBC

Pfizer will not sell drugs for profit in poor nations

US drugs giant Pfizer has said it will no longer make a profit from selling its patented medicines to 45 of the world's low-income countries.

May, 2022

Forbes

Pfizer Launches $3.5 Billion Cost-Cutting Program Amid Declining Covid Vaccine Sales

Pfizer expects the cost-cutting program to realize approximately $1 billion in savings in 2023 and at least $2.5 billion next year.

Oct, 2023

Competitive Landscape
Annual Revenue:
$58.50B
  • Pfizer has 88,000 employees globally.
  • Revenues growth in 2023 was $58.50B, reflecting 41% decrease from 2022.
  • Pfizer: Diverse pharmaceuticals including COVID-19 vaccine.
Annual Revenue:
$85.15B
  • J&J's has more than 130,000 employees worldwide.
  • J&J revenue growth 2023 was $85.15B, a 6.46% increase from 2022.
  • J&J: Pharmaceuticals, medical devices, consumer health products.
Annual Revenue:
$9.35B
  • Eli Lily has 43,000 employees globally.
  • Revenue growth 2023 was $9.35B, up 28% from 2023.
  • Eli Lilly: Innovative medicines and healthcare solutions.
Annual Revenue:
$33.72B
  • NVO has over 64,000 employees around the world.
  • Revenue for 2023 was $33.72B, up 34.59% from 2023.
  • Novartis (NVO): Innovative medicines, generics, eye care products.

Want help preparing for your next meeting?

Our zero-software service is designed to make you confident
and well-prepared before your most important meetings.